BIOMAT Database Logo BIOMAT Database Logo

Yellow fever immunization. 1969

D D Banker

UI MeSH Term Description Entries
D007110 Immunity, Active Resistance to a disease agent resulting from the production of specific antibodies by the host, either after exposure to the disease or after vaccination. Active Immune Response,Active Immune Responses,Active Immunities,Active Immunity,Immune Response, Active,Immune Responses, Active,Immunities, Active,Response, Active Immune,Responses, Active Immune
D007115 Immunization Schedule Schedule giving optimum times usually for primary and/or secondary immunization. Immunization Schedules,Schedule, Immunization,Schedules, Immunization
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014195 Travel MOVEMENT across different GEOGRAPHIC LOCATIONS. Land Travel,Sea Travel,Land Travels,Sea Travels,Travel, Land,Travel, Sea,Travels,Travels, Land,Travels, Sea
D014765 Viral Vaccines Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease. Viral Vaccine,Vaccine, Viral,Vaccines, Viral
D015004 Yellow Fever An acute infectious disease primarily of the tropics, caused by a virus and transmitted to man by mosquitoes of the genera Aedes and Haemagogus. The severe form is characterized by fever, HEMOLYTIC JAUNDICE, and renal damage. Fever, Yellow,Fevers, Yellow,Yellow Fevers
D015005 Yellow fever virus The type species of the FLAVIVIRUS genus. Principal vector transmission to humans is by AEDES spp. mosquitoes.

Related Publications

D D Banker
[Immunization against yellow fever].
May 2007, Revue medicale suisse,
D D Banker
Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1.
December 1986, Journal of virology,
D D Banker
[Homeopathic immunization against yellow fever in Havana, 1855].
January 1991, Asclepio; archivo iberoamericano de historia de la medicina y antropologia medica,
D D Banker
Benefit versus risk factors in immunization against yellow fever.
January 1979, Developments in biological standardization,
D D Banker
Congenital yellow fever virus infection after immunization in pregnancy.
December 1993, The Journal of infectious diseases,
D D Banker
[Effect of anticholera vaccination on associated anti-yellow fever immunization].
January 1973, Bulletin de la Societe de pathologie exotique et de ses filiales,
D D Banker
Yellow fever vaccine. Recommendations of the Immunization Practices Advisory Committee (ACIP).
May 1990, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports,
D D Banker
Yellow fever vaccine-associated adverse events following extensive immunization in Argentina.
March 2014, Vaccine,
D D Banker
The metabolic response to yellow fever immunization: protein-sparing modified fast.
February 1981, The American journal of clinical nutrition,
D D Banker
[Antibody responses in Japanese volunteers after immunization with yellow fever vaccine].
September 2002, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
Copied contents to your clipboard!